Repligen (NASDAQ:RGEN – Free Report) had its price target lifted by JPMorgan Chase & Co. from $170.00 to $210.00 in a research report released on Wednesday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. A number of other equities analysts also recently issued reports on the company. Stifel Nicolaus […]
Granite Bay Wealth Management LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 30,744 shares of the biotechnology company’s stock, valued at approximately $5,026,000. Granite Bay Wealth Management LLC owned […]
Brown Capital Management LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 0.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,445,213 shares of the biotechnology company’s stock after buying an additional 4,845 shares during the period. Repligen […]
Repligen (NASDAQ:RGEN – Get Free Report) was downgraded by Benchmark from a “buy” rating to a “hold” rating in a report released on Monday, FinViz reports. Other equities research analysts also recently issued research reports about the company. UBS Group lowered their price target on Repligen from $210.00 to $170.00 and set a “buy” rating […]
Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among […]